Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot Q07955: Variant p.His183Arg

Serine/arginine-rich splicing factor 1
Gene: SRSF1
Feedback?
Variant information Variant position: help 183 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help US The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance

Residue change: help From Histidine (H) to Arginine (R) at position 183 (H183R, p.His183Arg). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Change from medium size and polar (H) to large size and basic (R) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help 0 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Variant description: help In NEDFBA; uncertain significance. Any additional useful information about the variant.


Sequence information Variant position: help 183 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 248 The length of the canonical sequence.
Location on the sequence: help VRKEDMTYAVRKLDNTKFRS H EGETAYIRVKVDGPRSPSYG The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human                         VRKEDMTYAVRKLDNTKFRSHEGETAYIRVKVDGPRSPSYG

Mouse                         VRKEDMTYAVRKLDNTKFRSHEGETAYIRVKVDGPRSPSYG

Pig                           VRKEDMTYAVRKLDNTKFRSHEGETAYIRVKVDGPRSPSYG

Bovine                        VRKEDMTYAVRKLDNTKFRSHEGETAYIRVKVDGPRSPSYG

Chicken                       VRKEDMTYAVRKLDNTKFRSHEGETAYIRVKVDGPRSPSYG

Xenopus tropicalis            VRKEDMTYAVRKLDNTKFRSHEGETAYIRVKVDGPRSPSYG

Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 2 – 248 Serine/arginine-rich splicing factor 1
Domain 121 – 195 RRM 2
Modified residue 179 – 179 N6-acetyllysine
Modified residue 199 – 199 Phosphoserine
Modified residue 201 – 201 Phosphoserine
Modified residue 202 – 202 Phosphotyrosine
Mutagenesis 180 – 180 F -> D. Reduced nucleocytoplasmic shuttling; when associated with D-162.
Mutagenesis 182 – 248 Missing. In MR-B; strongly inhibits splicing.
Mutagenesis 182 – 199 Missing. In MR-E; loss of ability to activate splicing.
Beta strand 183 – 185



Literature citations
SRSF1 haploinsufficiency is responsible for a syndromic developmental disorder associated with intellectual disability.
Bogaert E.; Garde A.; Gautier T.; Rooney K.; Duffourd Y.; LeBlanc P.; van Reempts E.; Tran Mau-Them F.; Wentzensen I.M.; Au K.S.; Richardson K.; Northrup H.; Gatinois V.; Genevieve D.; Louie R.J.; Lyons M.J.; Laulund L.W.; Brasch-Andersen C.; Maxel Juul T.; El It F.; Marle N.; Callier P.; Relator R.; Haghshenas S.; McConkey H.; Kerkhof J.; Cesario C.; Novelli A.; Brunetti-Pierri N.; Pinelli M.; Pennamen P.; Naudion S.; Legendre M.; Courdier C.; Trimouille A.; Fenzy M.D.; Pais L.; Yeung A.; Nugent K.; Roeder E.R.; Mitani T.; Posey J.E.; Calame D.; Yonath H.; Rosenfeld J.A.; Musante L.; Faletra F.; Montanari F.; Sartor G.; Vancini A.; Seri M.; Besmond C.; Poirier K.; Hubert L.; Hemelsoet D.; Munnich A.; Lupski J.R.; Philippe C.; Thauvin-Robinet C.; Faivre L.; Sadikovic B.; Govin J.; Dermaut B.; Vitobello A.;
Am. J. Hum. Genet. 110:790-808(2023)
Cited for: VARIANTS NEDFBA LEU-24; 28-ARG--THR-248 DEL; 33-GLU--THR-248 DEL; VAL-40; ASN-44; THR-70; 77-TYR--THR-248 DEL; ARG-84; MET-160 AND ARG-183; INVOLVEMENT IN NEDFBA;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.